Urogen Pharma (URGN) News Today

UroGen Pharma (NASDAQ: URGN) reported strong growth in its commercial product, but investors focused on reduced 2026 guidance and quarterly results that disappointed some estimates. The shares came under pressure following the announcements.

• Positive Sentiment: ZUSDURI generated $68 million in third-quarter revenue, up 35% sequentially. The company also said repeat prescribers made up 50% of ZUSDURI writers, suggesting growing adoption. The Gel That Became a Business
• Positive Sentiment: The FDA accepted UroGen’s UGN-103 application for review and set a June 14, 2027 PDUFA goal date, providing a regulatory milestone for the next-generation therapy. UroGen also reported that the first patient was dosed in its UGN-501 Phase 1 trial. UroGen Q3 2026 results and highlights
• Negative Sentiment: UroGen cut its FY2026 guidance, a key source of investor concern. Although ZUSDURI sales were strong, reported quarterly revenue of $89 million was slightly below the cited $89.92 million consensus, and earnings coverage characterized the results as missing estimates. The company reported a loss of $0.03 per share; estimate comparisons varied across reports. UroGen stock falls on Q3 results and guidance cut